Posted inBiotechnology
Takeda turns to AI drug designer after whittling down R&D focus
After walking away from cell therapy and narrowing its focus to just three modalities, Takeda is doubling down on its…
Posted inGenetics
In Conversation with Visionary Geneticist George Church
George Church, PhD, joined us on September 24, 2025 as the opening keynote speaker during GEN’s flagship virtual summit “The…
Posted inGenetics
Using Human Organoids to Understand the Biology of Exposomes
Our cells are continually being exposed to environmental assaults. For instance, skin is exposed to pollutants and UV radiation. Our…
Posted inBiotechnology
Cabaletta CAR-T wipes out B cells without preconditioning in small autoimmune trial
Cabaletta Bio’s CAR-T cell therapy has eliminated the overreactive B cells of two patients with an autoimmune disease without preconditioning…
Posted inBiotechnology
Amid the dip, biotech execs share silver linings in a tumultuous environment
Ten months into 2025, and it’s clear the year hasn’t unfolded as many had expected—or hoped. Marked by a persistent…
Posted inBiotechnology
BMS inks $1.5B in vivo CAR-T buyout to pull Orbital into its sphere of influence
The stars have aligned for Bristol Myers Squibb and Orbital Therapeutics. Pushing deeper into in vivo cell therapies, BMS has agreed…
Posted inMedical Technology
Diagnostic maker Navidea’s winding path leads to Chapter 11 filing
Diagnostic and immunotherapy biopharma Navidea Biopharmaceuticals' long and often tortured journey is coming to an end as it files for…
Posted inBiotechnology
Shuttle Pharma launches into AI drug discovery space via $10M acquisition
Shuttle Pharmaceuticals has rocketed into the artificial-intelligence-driven drug discovery space via the planned $10 million acquisition of Molecule.ai. Until now,…
Posted inBiotechnology
Inflammation biotech Evommune eyes IPO to fund further dermatitis trials
Will the return of biotech IPOs become the hottest fashion trend this fall? It’s still early in the season, but…
Posted inBiotechnology
Regeneron amplifies CHORD progression, sharing updated data on hearing loss gene therapy
Regeneron has posted updated clinical data on DB-OTO, providing more evidence of the gene therapy’s potential to treat a rare…